Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Enzalutamide in metastatic prostate cancer before chemotherapy.
|
N Engl J Med
|
2014
|
11.05
|
2
|
Contemporary role of androgen deprivation therapy for prostate cancer.
|
Eur Urol
|
2011
|
2.68
|
3
|
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
|
Lancet Oncol
|
2015
|
2.41
|
4
|
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.
|
Clin Cancer Res
|
2011
|
2.01
|
5
|
Novel therapies for metastatic castrate-resistant prostate cancer.
|
J Natl Cancer Inst
|
2011
|
1.98
|
6
|
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.
|
Oncogene
|
2014
|
1.31
|
7
|
Androgen action and metabolism in prostate cancer.
|
Mol Cell Endocrinol
|
2012
|
1.25
|
8
|
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.
|
Prostate Cancer Prostatic Dis
|
2013
|
1.22
|
9
|
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
|
J Clin Oncol
|
2016
|
1.21
|
10
|
Androgen receptor antagonists in castration-resistant prostate cancer.
|
Cancer J
|
2013
|
1.19
|
11
|
Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit.
|
Clin Cancer Res
|
2013
|
1.13
|
12
|
Overview of the latest treatments for castration-resistant prostate cancer.
|
Nat Rev Urol
|
2013
|
1.12
|
13
|
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
|
J Hematol Oncol
|
2011
|
1.05
|
14
|
Emerging novel therapies in the treatment of castrate-resistant prostate cancer.
|
Can Urol Assoc J
|
2011
|
1.04
|
15
|
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.
|
Cancer Manag Res
|
2013
|
1.00
|
16
|
The changing landscape in the treatment of metastatic castration-resistant prostate cancer.
|
Ther Adv Med Oncol
|
2013
|
0.97
|
17
|
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.
|
Ther Adv Urol
|
2014
|
0.96
|
18
|
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.
|
Prostate Cancer Prostatic Dis
|
2011
|
0.93
|
19
|
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
|
Prostate
|
2014
|
0.92
|
20
|
Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.
|
Nat Rev Urol
|
2012
|
0.91
|
21
|
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
|
Oncologist
|
2011
|
0.90
|
22
|
Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions.
|
Curr Oncol
|
2012
|
0.89
|
23
|
Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer.
|
Ther Adv Urol
|
2013
|
0.89
|
24
|
Cell mates: paracrine and stromal targets for prostate cancer therapy.
|
Nat Rev Urol
|
2013
|
0.87
|
25
|
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.
|
Asian J Androl
|
2011
|
0.87
|
26
|
Novel agents in the management of castration resistant prostate cancer.
|
J Carcinog
|
2014
|
0.87
|
27
|
Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.
|
Cancer Biol Ther
|
2013
|
0.85
|
28
|
Emerging molecularly targeted therapies in castration refractory prostate cancer.
|
Prostate Cancer
|
2013
|
0.83
|
29
|
Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.
|
Drug Des Devel Ther
|
2013
|
0.83
|
30
|
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
|
Ann Oncol
|
2015
|
0.82
|
31
|
Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer.
|
Core Evid
|
2013
|
0.82
|
32
|
Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.
|
Expert Rev Anticancer Ther
|
2014
|
0.82
|
33
|
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
|
Eur Urol
|
2016
|
0.82
|
34
|
Emerging targeted therapies for castration-resistant prostate cancer.
|
Front Endocrinol (Lausanne)
|
2012
|
0.81
|
35
|
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer.
|
Int J Biol Sci
|
2016
|
0.81
|
36
|
U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
|
Oncologist
|
2015
|
0.81
|
37
|
Abiraterone acetate.
|
Nat Rev Drug Discov
|
2011
|
0.80
|
38
|
Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer.
|
Drugs
|
2013
|
0.80
|
39
|
New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer.
|
Prostate Cancer
|
2011
|
0.79
|
40
|
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.
|
Cancer Biol Ther
|
2012
|
0.79
|
41
|
Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect Comparison.
|
Clin Med Insights Oncol
|
2014
|
0.79
|
42
|
An update on enzalutamide in the treatment of prostate cancer.
|
Ther Adv Urol
|
2015
|
0.79
|
43
|
Metastatic castration-resistant prostate cancer: critical review of enzalutamide.
|
Clin Med Insights Oncol
|
2013
|
0.78
|
44
|
A changing landscape in castration-resistant prostate cancer treatment.
|
Front Endocrinol (Lausanne)
|
2012
|
0.78
|
45
|
Unmet needs in the prediction and detection of metastases in prostate cancer.
|
Oncologist
|
2013
|
0.78
|
46
|
Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer.
|
Asian J Androl
|
2012
|
0.78
|
47
|
Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy.
|
J Clin Immunol
|
2011
|
0.78
|
48
|
Prostate cancer: Are urologists ready to manage castration-resistant disease?
|
Nat Rev Urol
|
2013
|
0.77
|
49
|
Radium-223 chloride: a new treatment option for metastatic castration-resistant prostate carcinoma.
|
Drugs R D
|
2012
|
0.77
|
50
|
Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer.
|
Drug Discov Today Ther Strateg
|
2010
|
0.76
|
51
|
Management of metastatic castration-resistant prostate cancer.
|
Eur Urol Rev
|
2011
|
0.75
|
52
|
Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks.
|
Nat Rev Clin Oncol
|
2012
|
0.75
|
53
|
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
|
Eur Urol
|
2020
|
0.75
|
54
|
The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients.
|
Investig Clin Urol
|
2016
|
0.75
|
55
|
Castrate-resistant prostate cancer: postdocetaxel management.
|
Curr Opin Urol
|
2013
|
0.75
|